Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase III Attain-Maintain trial with ...

In an announcement Monday, Nov. 3, the Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and other oral medicines. Lilly expects to ...

Eli Lilly has developed artificial intelligence models that can help predict the behavior of potential drug candidates, based on the data the drugmaker has collected over the last two decades and at ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

Kernal Biologics, Inc., a venture-backed therapeutics company developing novel therapeutics to program human cells directly inside the body, today announced its relocation to Lilly Gateway Labs (LGL) ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly's recent 20% pullback is a buy-the-dip opportunity, as the market overreacted to mixed Orforglipron results. Blockbuster drugs Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up ...